

synthetic peptides containing the RGD or dodecapeptide have been shown to bind to the platelet GPIIb/IIIa receptor and competitively inhibit binding of fibrinogen, fibronectin and von Willebrand factor as well as inhibit aggregation of activated platelets (Plow, et al., *Proc. Natl. Acad. Sci. USA* 1985, 82, 8057-61; Ruggeri, et al., *Proc. Natl. Acad. Sci. USA* 1986, 5708-12; Ginsberg, et al., *J. Biol. Chem.* 1985, 260, 3931-36; and Gartner, et al., *J. Biol. Chem.* 1987, 260, 11, 891-94).--

Please replace the paragraph commencing at page 2, line 37, with the following rewritten paragraph.

--Haverstick, D.M., et al., in *Blood* 66 (4), 946-952 (1985), disclose that a number of synthetic peptides are capable of inhibiting thrombin-induced platelet aggregation.--

Please replace the paragraph commencing at page 3, line 2, with the following rewritten paragraph.

--Plow, E.F., et al., in *Proc. Natl. Acad. Sci. USA* 79, 3711-3715 (1982), disclose that a tetrapeptide which inhibits fibrinogen binding to human platelets.--

In the Abstract

Please replace the abstract with the following rewritten abstract.

The present invention relates to peptides and pseudopeptides which inhibit platelet aggregation and thrombus formation thereby being useful in the prevention and treatment of thrombosis associated with disease states such as myocardial